Structure rises after obesity pill shows up to 16.3% weight loss in study

Structure Therapeutics

16/03/2026 11:28

** Shares of drug developer Structure Therapeutics GPCR.O rise 15.3% to $61.95 premarket
** Co says its oral obesity drug aleniglipron delivered up to 16.3% weight loss, when compared with a placebo after 44 weeks of treatment in a mid‑stage study

** Drug developers are racing to enter the highly competitive weight-loss drug market which is currently dominated by injectable drugs like Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound

** Analysts have previously estimated that weight loss of up to 16% would make Structure's aleniglipron competitive with other pills

** Guggenheim Securities says "in our view, most critical was the extended tolerability now through median 20 weeks of treatment that appears highly competitive on vomiting and discontinuations while maintaining strong and consistent weight loss"

** At 36 weeks, aleniglipron had shown weight loss of up to 15.3% at the 240 mg dose - GPCR

** Co says there has been no sign of plateauing in weight loss across studies
** GPCR expects to begin late-stage study in H2 2026

** Up to last close, GPCR down 22.7% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))